Our Researchers | LLNI Funding 2026
Successful new treatments, repurposed drugs or new drug combinations can then be used in clinical trials and ultimately can be offered by Haematology consultants as new, specialised treatments for their patients.
Katrina Lappin
LLNI Fellow exploring immune activation in MDS and AML, and how we can exploit the immune response to target leukaemic cells.
Graeme Greenfield
Academic Clinical Fellow. How do individual AML cells adapt to avoid cell death after treatment with azacitidine and venetoclax in individual patients.
Hayley McMillan
Understanding the genetic mutations in myeloid malignancies at diagnosis and during disease progression, and to also identify specific drug combinations that inhibit these mutations.
Lydia Roets
CURED Study Characterising drivers of therapeUtic Resistance in paEDiatric AML (CURED study).
Rebecca Briggs
Investigating the relationship between DNA damage and immune response activation in certain types of blood cancers
Our PhD Researchers 2026
LLNI provides funding to PhD researchers who are looking at various different blood cancers.
Chloe Wylie
Exosome-mediated molecular mechanisms in the progression of multiple myeloma.
Edward Tang
Understanding primary chemotherapy resistance in childhood acute myeloid leukaemia.
Beth McCrea
Developing small molecule inhibitors to target HUWE1 mutation.
Deepti Kasi
The role of protein degradation in multiple myeloma.
Fionnuala Petticrew
The Simon Robinson PhD Studentship: identifying new therapeutic targets in Diffuse Large B Cell Lymphoma, aiming to restore cell death pathways in cancer cells using a recently developed drug.
Lucy Wilson
Identification of potential cancer vaccine targets for Acute Myeloid Leukaemia
Claire Kelly
Evaluating DNA Uracilation as a Targeted Therapeutic Strategy in Acute Lymphoblastic Leukaemia
Aidan Kilmartin
Exploring the role of mRNA and protein quality control mechanisms in driving acute myeloid leukaemia (AML) progression and therapeutic resistance.
Ciara Cunningham
Enhancing therapeutic response in Diffuse Large B-Cell Lymphoma (DLBCL) through investigating the role of metabolic regulators.
Scientific and Medical Committee
A panel of independent researchers and clinicians who provide recommendations to Leukaemia & Lymphoma NI on decisions relating to the funding and management of research projects.
Dr Kathryn Clarke
Vice Chair
Principal Clinical Scientist | Haemato-oncology Department of Haematology Belfast City Hospital
Dr Aaron Niblock
Chair
Haematology Consultant Antrim Hospital
Dr Lynn McCallum
Associate Professor in Haematology (Education) Programme Lead Healthcare Sciences University of Plymouth Programme Lead Applied Biomedical Sciences Programme Lead Clinical Physiology
Dr Brídgín Merron
Glenda Joanne Dickson
Principal Scientist, Innovation Virocell
They ensure that all LLNI funding awards support the highest quality research and will consider applications for funding for basic, translational and clinical related research.